Distribution and clinical correlates of viral and host genotypes in Chinese patients with chronic hepatitis C virus infection

Journal of Gastroenterology and Hepatology (Australia)

Volumn 29, Issue 3, 2014, Pages 545-553

  Rao, Huiying ^a   Wei, Lai ^a   Lopez Talavera, Juan Carlos ^ad   Shang, Jia ^d   Chen, Hong ^f   Li, Jun ^g   Xie, Qing ^h   Gao, Zhiliang ^j   Wang, Lei ^l   Wei, Jia ^m   Jiang, Jianning ⁿ   Sun, Yongtao ^o   Yang, Ruifeng ^a   Li, Hong ^ad   Zhang, Haiying ^a   Gong, Zuojiong ^p   Zhang, Lunli ^r   Zhao, Longfeng ^s   Dou, Xiaoguang ^t   Niu, Junqi ^u   You, Hong ^b   Chen, Zhi ^v   Ning, Qin ^q   Gong, Guozhong ^w   Wu, Shuhuan ^e   Ji, Wei ^x   Mao, Qing ^y   Tang, Hong ^z   Li, Shuchen ^aa   Wei, Shaofeng ^ab   Sun, Jian ^k   Jiang, Jiaji ^ac   Lu, Lungen ⁱ   Jia, Jidong ^b   Zhuang, Hui ^c   more..

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^d HENAN PROVINCIAL PEOPLE'S HOSPITAL   (China)

^e THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIVERSITY   (China)

^f LANZHOU UNIVERSITY   (China)

^g THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

^h SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

ⁱ SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^j THE THIRD AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^k SOUTHERN MEDICAL UNIVERSITY   (China)

^l THE SECOND HOSPITAL OF SHANDONG UNIVERSITY   (China)

^m KUNMING MEDICAL UNIVERSITY   (China)

ⁿ FIRST AFFILIATED HOSPITAL OF GUANGXI MEDICAL UNIVERSITY   (China)

^o FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^p RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

^q HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^r NANCHANG UNIVERSITY   (China)

^s SHANXI MEDICAL UNIVERSITY   (China)

^t CHINA MEDICAL UNIVERSITY   (China)

^u THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

^v ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^w CENTRAL SOUTH UNIVERSITY   (China)

^x People's Hospital of Ningxia Hui   (China)

^y SOUTHWEST HOSPITAL   (China)

^z SICHUAN UNIVERSITY   (China)

^aa THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^ab ANHUI MEDICAL UNIVERSITY   (China)

^ac FUJIAN MEDICAL UNIVERSITY   (China)

^ad BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

China; Cirrhosis; Epidemiology; HPV; IL28B; Natural history

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN GLUCURONIDE; INTERLEUKIN 28B;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOL CONSUMPTION; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD TRANSFUSION; BODY PIERCING; CHINESE; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE TRANSMISSION; FEMALE; FOOD INTAKE; GENETIC TRAIT; GENOTYPE; HEPATITIS B VIRUS; HEPATITIS C; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; INTERNATIONAL NORMALIZED RATIO; INTRAVENOUS DRUG ABUSE; LIFESTYLE; LIVER BIOPSY; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MIXED INFECTION; OBSERVATIONAL STUDY; PORTAL HYPERTENSION; PRIORITY JOURNAL; SPLENOMEGALY; TATTOO; VIRAL GENETICS; VIRUS LOAD; VIRUS TRANSMISSION;

CHINA; CIRRHOSIS; EPIDEMIOLOGY; HPV; IL28B; NATURAL HISTORY;

ADULT; ASIAN CONTINENTAL ANCESTRY GROUP; CHINA; COINFECTION; CROSS-SECTIONAL STUDIES; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS B; HEPATITIS C, CHRONIC; HUMANS; INTERLEUKINS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS;

EID: 84897653506     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12398     Document Type: Article

References (40)

1. Sievert W, Altraif I, Razavi HA etal. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int. 2011; 31 (Suppl. 2): 61-80.
2. Chen YD, Liu MY, Yu WL etal. Hepatitis C virus infections and genotypes in China. Hepatobiliary Pancreat. Dis. Int. 2002; 1: 194-201.
3. Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-1374.
4. Jacobson IM, McHutchison JG, Dusheiko G etal. Telaprevir for previously untreated chronic hepatitis C virus infection. N. Engl. J. Med. 2011; 364: 2405-2416.
5. Poordad F, McCone J Jr, Bacon BR etal. Boceprevir for untreated chronic HCV genotype 1 infection. N. Engl. J. Med. 2011; 364: 1195-1206.
6. Legrand-Abravanel F, Colson P, Leguillou-Guillemette H etal. Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. J. Med. Virol. 2009; 81: 2029-2035.
7. Thompson AJ, Muir AJ, Sulkowski MS etal. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010; 139: 120-129.
8. Thomas DL, Thio CL, Martin MP etal. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
9. Rao HY, Sun DG, Jiang D etal. IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection. J. Viral Hepat. 2012; 19: 173-181.
10. Lu L, Nakano T, He Y, Fu Y, Hagedorn CH, Robertson BH. Hepatitis C virus genotype distribution in China: predominance of closely related subtype 1b isolates and existence of new genotype 6 variants. J. Med. Virol. 2005; 75: 538-549.
11. Zhang YY, Lok AS, Chan DT, Widell A. Greater diversity of hepatitis C virus genotypes found in Hong Kong than in mainland China. J. Clin. Microbiol. 1995; 33: 2931-2934.
12. Fu Y, Wang Y, Xia W etal. New trends of HCV infection in China revealed by genetic analysis of viral sequences determined from first-time volunteer blood donors. J. Viral Hepat. 2011; 18: 42-52.
13. National Bureau of Statistics of China. China Statistical Yearbook 2010: Total population by urban and rural residence and birth rate, death rate, natural growth rate by region (2009) 2010. Cited 15 Oct 2010. Available from URL: http://www.stats.gov.cn/tjsj/ndsj/2009/indexch.htm.
14. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-1236.
15. Farrell GC, Chitturi S, Lau GK, Sollano JD, Asia-Pacific Working Party on NAFLD. Guidelines for the assessment and management of non-alcoholic fatty liver disease in the Asia-Pacific region: executive summary. J. Gastroenterol. Hepatol. 2007; 22: 775-777.
16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2004; 27 (Suppl. 1): S5-S10.
17. Wigginton JE, Cutler DJ, Abecasis GR. A note on exact tests of Hardy-Weinberg equilibrium. Am. J. Hum. Genet. 2005; 76: 887-893.
18. Ge D, Fellay J, Thompson AJ etal. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
19. Tanaka Y, Nishida N, Sugiyama M etal. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat. Genet. 2009; 41: 1105-1109.
20. Suppiah V, Moldovan M, Ahlenstiel G etal. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat. Genet. 2009; 41: 1100-1104.
21. Xia X, Lu L, Tee KK etal. The unique HCV genotype distribution and the discovery of a novel subtype 6u among IDUs co-infected with HIV-1 in Yunnan, China. J. Med. Virol. 2008; 80: 1142-1152.
22. Zhang C, Wu N, Liu J etal. HCV subtype characterization among injection drug users: implication for a crucial role of Zhenjiang in HCV transmission in China. PLoS ONE 2011; 6: e16817.
23. Zhou Y, Wang X, Mao Q etal. Changes in modes of hepatitis C infection acquisition and genotypes in southwest China. J. Clin. Virol. 2009; 46: 230-233.
24. Nelson PK, Mathers BM, Cowie B etal. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011; 378: 571-583.
25. Bao YP, Liu ZM, Lu L. Review of HIV and HCV infection among drug users in China. Curr. Opin. Psychiatry 2010; 23: 187-194.
26. Lai S, Chen J, Celentano D etal. Adoption of injection practices in heroin users in Guangxi Province, China. J. Psychoactive Drugs 2000; 32: 285-292.
27. Shan H, Wang JX, Ren FR etal. Blood banking in China. Lancet 2002; 360: 1770-1775.
28. Chen JY, Lin CY, Wang CM etal. IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-alpha plus ribavirin therapy in Taiwanese chronic HCV infection. Genes Immun. 2011; 12: 300-309.
29. Lin CY, Chen JY, Lin TN etal. IL28B SNP rs12979860 is a critical predictor for on-treatment and sustained virologic response in patients with hepatitis C virus genotype-1 infection. PLoS ONE 2011; 6: e18322.
30. Yu ML, Dai CY, Huang JF etal. Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: a randomized trial. Hepatology 2008; 47: 1884-1893.
31. Kuboki M, Iino S, Okuno T etal. Peginterferon alpha-2a (40KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients. J. Gastroenterol. Hepatol. 2007; 22: 645-652.
32. McHutchison JG, Lawitz EJ, Shiffman ML etal. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N. Engl. J. Med. 2009; 361: 580-593.
33. Chayama K, Takahashi S, Toyota J etal. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology 2012; 55: 742-748.
34. Coffin CS, Terrault NA. Management of patients co-infected with HBV and HCV. Expert Rev. Anti Infect. Ther. 2009; 7: 549-558.
35. Duvoux C, Pawlotsky JM, Bastie A, Cherqui D, Soussy CJ, Dhumeaux D. Low HCV replication levels in end-stage hepatitis C virus-related liver disease. J. Hepatol. 1999; 31: 593-597.
36. Giannini E, Risso D, Botta F etal. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch. Intern. Med. 2003; 163: 218-224.
37. Veldt BJ, Chen W, Heathcote EJ etal. Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 2008; 47: 1856-1862.
38. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: a seventeen-year prospective cohort study. Hepatology 2007; 46: 1350-1356.
39. Lee MH, Yang HI, Lu SN etal. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: long-term predictors from a community-based cohort study. J. Clin. Oncol. 2010; 28: 4587-4593.
40. Jin X, Zheng RH, Li YM. Green tea consumption and liver disease: a systematic review. Liver Int. 2008; 28: 990-996.